WO1992014138A1 - Procede et dispositif d'analyse utilisant la luminescence magnetique basee sur des microparticules magnetiques et comprenant une pluralite d'aimants - Google Patents

Procede et dispositif d'analyse utilisant la luminescence magnetique basee sur des microparticules magnetiques et comprenant une pluralite d'aimants Download PDF

Info

Publication number
WO1992014138A1
WO1992014138A1 PCT/US1992/000982 US9200982W WO9214138A1 WO 1992014138 A1 WO1992014138 A1 WO 1992014138A1 US 9200982 W US9200982 W US 9200982W WO 9214138 A1 WO9214138 A1 WO 9214138A1
Authority
WO
WIPO (PCT)
Prior art keywords
assay
electrode
particles
ecl
analyte
Prior art date
Application number
PCT/US1992/000982
Other languages
English (en)
Inventor
John K. Leland
Haresh P. Shah
John H. Kenten
Jack E. Goodman
George E. Lowke
Yuzaburo Namba
Gary F. Blackburn
Richard J. Massey
Original Assignee
Igen, Inc.
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igen, Inc., Eisai Co., Ltd. filed Critical Igen, Inc.
Priority to JP4507261A priority Critical patent/JP3013937B2/ja
Publication of WO1992014138A1 publication Critical patent/WO1992014138A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6825—Nucleic acid detection involving sensors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/66—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/30—Electrochemically active labels

Definitions

  • This invention relates to a method for performing a binding assay for an analyte of interest present in a sample based upon measurement of electroche iluminescence at an electrode wherein a complex including the sample, an assay-performance substance containing a component linked to a label capable of being induced to electrochemiluminesce, and a plurality of magnetically responsive suspended particles capable of binding with the analyte or substance is formed; the complex is collected at the surface of an electrode by the imposition of a magnetic field on the particles by a plurality of permanent magnets or electromagnets in north-south orientation; the label is induced to luminesce; and, the luminescence emitted is measured.
  • the invention also relates to apparatus for performing such a method having the plurality of permanent magnets or electromagnets in north-south orientation.
  • Photoluminescence is the process whereby a material is induced to luminesce when it absorbs electromagnetic radiation. Fluorescence and phosphorescence are types of photoluminescence.
  • Cyhemiluminescent processes entail the creation of luminescent species by chemical transfer of energy.
  • “Electrochemiluminescence” entails creation of luminescent species electrochemically.
  • Chemiluminescent assay techniques where a sample containing an analyte of interest is mixed with a reactant labeled with a chemiluminescent label have been developed. The reactive mixture is incubated and some portion of the labeled reactant binds to the analyte. After incubation, the bound and unbound fractions of the mixture are separated and the concentration of the label in either or both fractions can be determined by chemiluminescent techniques. The level of chemiluminescence determined in one or both fractions indicates the amount of analyte of interest in the biological sample. Electrochemiluminescent (ECL) assay techniques are an improvement on chemiluminescent techniques.
  • ECL Electrochemiluminescent
  • U.S. Patent No. 4,305,925 relates to the detection and determination of clinically relevant proteins and peptides by means of nephelometric and tur- bidi etric methods. The methods disclosed involve binding the antigen or antibody to latex particles which perform the function of light scattering or adsorption.
  • U.S. Patent No. 4,480,042 relates to techniques employing particle reagents consisting of shell-core particles. The shell contains functional groups to which compounds of biological interest can be covalently bonded, and the high refractive index of the core results in high sensitivity to light scattering measurements.
  • U.S. Application Serial No. 539,389 (PCT published application U.S. 89/04919) teaches sensitive, specific binding assay methods based on a luminescent phenomenon wherein inert microparticulate matter is specifically bound to one of the binding reactants of the assay system.
  • the assays may be performed in a heterogeneous (one or more separation steps) assay format and may be used most advantageously in a homogeneous (nonseparation) assay format.
  • U.S. 89/04919 relates to a composition for an assay based upon a binding reaction for the measurement of luminescent phenomenon, which composition includes a plurality of suspended particles having a surface capable of binding to a component of the assay mixture.
  • it is directed to a system for detecting or quantitating an analyte of interest in a sample, which system is capable of conducting the assay methods using the assay compositions of the inventions.
  • the system includes means for inducing the label compound in the assay medium to luminesce, and means for measuring the luminescence to detect the presence of the analyte of interest in the sample.
  • U.S. 89/04919 is directed to methods for the detection of an analyte of interest in a sample, which method includes the steps of (1) forming a composition comprising (a) a sample suspected of containing an analyte of interest, (b) an assay- performance-substance selected from the group consisting of (i) analyte of interest or analog of the analyte of interest, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a reactive component capable of binding with (i) or (ii) , wherein one of said substances is linked to a label compound having a chemical moiety capable of being induced to luminesce, and (c) a plurality of suspended particles capable of specifically binding with the analyte and/or a substance defined in (b) (i) , (ii) , or (iii) ; (2) incubating the composition to form a complex which includes a particle and said label compound; (3) incuba
  • Analogs of the analyte of interest which may be natural or synthetic, are compounds which have binding properties comparable to the analyte, but include compounds of higher or lower binding capability as well. Binding partners suitable for use in the present invention are well-known. Examples are antibodies, enzymes, nucleic acids, lectins, cofactors and receptors.
  • the reactive components capable of binding with the analyte or its analog and/or with a binding partner thereof may be a second antibody or a protein such as Protein A or Protein G or may be avidin or biotin or
  • SUBSTITUTE SHEET another component known in the art to enter into binding reactions.
  • the luminescence arises from electrochemiluminescence (ECL) induced by exposing the label compound, whether bound or unbound to specific binding partners, to a voltammetric working electrode.
  • ECL electrochemiluminescence
  • the ECL reactive mixture is controllably triggered to emit light by a voltage impressed on the working electrode at a particular time and in a particular manner to generate light.
  • the emission of visible light is an advantageous feature the composition or system may emit other types of electromagnetic radiation, such as infrared or ultraviolet light, X-rays, microwaves, etc.
  • Use of the terms "electrochemiluminescence,” “electrochemiluminescent,” “luminescence,” “luminescent,” and “luminesce” includes the emission of light and other forms of electromagnetic radiation.
  • the probability of the tunneling phenomenon falls off exponentially as the distance between the two species increases.
  • the probability of the tunneling phenomenon occurring between two species is fairly high if the distance is less than 25 Angstroms (2.5 nm) but is fairly low if the distance is greater.
  • the distance of 25 A is a rule-of-thumb used by those skilled in the art but is not an absolute limitation.
  • ECL moiety "metal-containing ECL moiety” "label,” “label compound,” and “label substance,” are used interchangeably. It is within the scope of the invention for the species termed “ECL moiety,” “metal- containing ECL moiety,” “organo-metallic,” “metal chelate,” “transition metal chelate” “rare earth metal chelate,” “label compound,” “label substance” and “label” to be linked to molecules such as an analyte or an analog thereof, a binding partner of the analyte or an analog thereof, and further binding partners of such aforementioned binding partner, or a reactive component capable of binding with the analyte, an analog thereof or a binding partner as mentioned above.
  • the above- mentioned species can also be linked to a combination of one or more binding partners and/or one or more reactive components. Additionally, the aforementioned species can also be linked to an analyte or its analog bound to a binding partner, a reactive component, or a combination of one or more binding partners and/or one or more reactive components. It is also within the scope of the invention for a plurality of the aforementioned species to be bound directly, or through other molecules as discussed above, to an analyte or its analog. For purposes of brevity, these ligands are referred to as an assay-performance-substance.
  • collection and concentration of complex may be used interchangeably to describe the concentration of complex within the assay composition and the collection of complex at, e.g., an electrode surface.
  • Figs. 1 and 2 show the cell and plurality of magnets for performing the magnetic microparticulate- based separation or non-separation assay method of the invention; the plurality of magnets of the magnet system imposes field lines which are largely parallel to the plane of the electrode surface.
  • Fig. 3 is a schematic representation of a sedimentation assay cell which employs electromagnets of Figs. 1 and 2 to cause the complex to settle on the electrode surface.
  • Fig. 4 is a graph showing the relative rates of settling of microparticulate complex under the influence of a magnetic field (Figs. 1 and 2) and of gravity, respectively, i.e., a comparison of microparticulate settling times between a magnetic field (Figs. 1, 2) induced settling and gravity settling wherein values for the magnetic field settling are represented by open circles and the values for gravity settling are represented by darkened circles.
  • Fig. 5 is a schematic representation of a collection cell including a permanent magnets of Figs. 1 and 2.
  • Fig. 6 is a graph showing the increase in ECL intensity as a function of time in assays conducted with the cell of Fig. 5, i.e., the effect of collection time on ECL intensity.
  • Fig. 7 is a schematic representation of the lines of force in the vicinity of the electrode surface of the magnets (Figs. 1 and 2) beneath the electrode surface.
  • Fig. 8 is a schematic drawing of a cell for performing the microparticulate-based nonseparation and separation assays of the invention; the cell employs a working electrode and plurality of magnets as in Figs. 1 and 2.
  • Fig. 9 is a simplified diagram of a voltage control apparatus for use with the cell of Fig. 8.
  • the invention is in a method for performing a binding assay for an analyte of interest present in a sample.
  • the steps include: (a) forming a composition containing (i) said sample (ii) an assay-performance-substance which contains a component linked to a label compound capable of being
  • the invention also provides an apparatus for performing a binding assay for an analyte of interest present in a sample based upon measurement of electrochemiluminescence at an electrode surface comprising:
  • SUBSTITUTE SHEET means for obtaining an even distribution of complex includes means for generating a magnetic field oriented with respect to said electrode so that the lines of force of said magnetic field are substantially parallel with the surface of said electrode in the region of said surface; and the means for generating a magnetic field includes a plurality of magnets in north-south orientation and separated by non-magnetic material positioned vertically below said electrode.
  • Several different heterogeneous and homogeneous formats for binding assays can be implemented using the method described above to collect and concentrate the complex on the surface of an electrode. In a heterogeneous binding assay the complex is separated from the composition before measuring luminescence from the label. In homogeneous assays, no separation of the bound (to the solid phase) and unbound labeled reagents is made.
  • the measured signal from the label is much greater than it would be in the absence of a collection step.
  • the signal from the uncomplexed labeled reagents in contrast, is not changed.
  • the signal from the collected complex is stronger than in an assay without collection of complex.
  • the detection limit for the binding assay is, much improved as a result of the collection procedure.
  • an in-situ separation step can be included in the homogeneous binding assay procedure.
  • a second fluid is pumped through the cell which is free of label or labeled reagents, thereby performing an in-situ wash or
  • SUBSTITUTE SHEET separation of the complex from unbound components of the assay composition is technically a heterogeneous binding assay.
  • the ability to perform the separation inside the measurement cell is advantageous in that it does not require additional separation apparatus and the procedure is generally much faster than external separation methods.
  • Heterogeneous binding assays are conducted using the invention by mixing the components of the assay composition and allowing them to react for a predetermined length of time.
  • the assay composition is then subjected to a separation step wherein the solution is separated from the particles .
  • Electrochemiluminescence is then measured from either the complex or the solution. Measuring the ECL from the complex after a concentration step permits measurement of analyte with better accuracy and with a lower detection limit than is possible without concentration.
  • the invention is broadly applicable to analytes of interest which are capable of entering into binding reactions. These reactions include, e.g., antigen- antibody, ligand receptor, DNA and RNA interactions, and other known reactions.
  • the invention relates to a method and apparatus for qualitatively and quantitatively detecting the presence of such analytes of interest in a multicomponent sample; the method and apparatus involve a plurality of north-south magnets.
  • the Samples which may contain the analyte of interest, which may be in solid, emulsion, suspension, liquid, or gas form, may be derived from, for example.
  • the sample may further comprise, for example, water, acetonitrile, dimethyl sulfoxide, dimethyl formamide, n-methyl-pyrrolidone or alcohols or mixtures thereof.
  • Typical analytes of interest are a whole cell or surface antigen, subcellular particle, virus, prion, viroid, antibody, antigen, hapten, fatty acid, nucleic acid, protein, lipoprotein, polysaccharide, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, synthetic organic molecule, organometallic molecule, tranquilizer, barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, lectin, recombinant or derived protein, biotin, avidin, streptavidin, or inorganic molecule present in the sample.
  • the analyte of interest is present at a concentration of 10 ⁇ 3 molar or less, for example, as low as 10 ⁇ 12 molar or lower.
  • the assay-performance-substance which is combined with the sample containing the analyte of interest contains at least one substance selected from the group consisting of (i) added analyte of interest or its analog, as defined above, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a reactive component, as defined above, capable of binding with (i) or (ii) , wherein one of said substances is linked to a compound or moiety, e.g. an ECL moiety capable of being induced to luminesce.
  • a compound or moiety e.g. an ECL moiety capable of being induced to luminesce.
  • the labeled substance may be a whole cell or surface antigen, a subcellular particle, virus, prion, viroid, antibody, antigen, hapten, lipid, fatty acid, nucleic acid, polysaccharide, protein, lipoprotein, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, tranquilizer, barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, nonbiological polymer (preferably soluble) , lectin, recombinant or derived protein, synthetic organic molecule, organometallic molecule, inorganic molecule, biotin, avidin or streptavidin.
  • the reagent is an electrochemiluminescent moiety conjugated to an antibody, antigen, nucleic acid, hapten, small nucleotide sequence, oligomer, ligand, enzyme, or biotin, avidin, streptavidin. Protein A, Protein G, or complexes thereof, or other secondary binding partner capable of binding to a primary binding partner through protein interactions.
  • Analogs of the analyte of interest are typically compounds which have binding properties comparable to the analyte, but can also be compounds of higher or lower binding capability.
  • the reactive component capable of binding with the analyte or its analog, and/or with a binding partner thereof, and through which the ECL moiety can be linked to the analyte is suitably a second antibody or a protein such as Protein A or Protein G, or avidin or biotin or another component known in the art to enter into binding reactions.
  • the Labels are metal chelates.
  • the metal of that chelate is suitably any metal such that the metal chelate will luminesce under the electrochemical conditions which are imposed on the reaction system in question.
  • the metal of such metal chelates is, for instance, a transition metal (such as a d-block transition metal) or a rare earth metal.
  • the metal is preferably ruthenium, osmium, rhenium, iridium, rhodium, platinum, indium, palladium, molybdenum, tech- netium, copper, chromium or tungsten. Especially preferred are ruthenium and osmium.
  • the ligands which are linked to the metal in such chelates are usually heterocyclic or organic in
  • the ligands can be polydentate, and can be substituted.
  • Polydentate ligands include aromatic and aliphatic ligands.
  • Suitable aromatic polydentate ligands include aromatic heterocyclic ligands.
  • Preferred aromatic heterocyclic ligands are nitrogen-containing, such as, for example, bipyridyl, bipyrazyl, terpyridyl, and phenanthrolyl.
  • Suitable substituents include for example, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, carboxylate, carboxaldehyde, carboxamide, cyano, amino, hydroxy, imino, hydroxycarbonyl, aminocarbonyl, amidine, guanidinium, ureide, sulfur-containing groups, phosphorus containing groups, and the carboxylate ester of N-hydroxy- succinimide.
  • the chelate may have one or more monodentate ligands, a wide variety of which are known to the art. Suitable monodentate ligands include, for example, carbon monoxide, cyanides, isocyanides, halides, and aliphatic, aromatic and heterocyclic phosphines, amines, stilbenes, and arsines.
  • Suitable chelates are bis [(4,4'- carbomethoxy)-2,2'-bipyridine] 2-[3-(4-methyl-2,2'-bi- pyridine-4-yl)propyl]-l,3-dioxolane ruthenium (II); bis (2,2'bipyridine) [4-(butan-1-al)-4'-methyl-2,2'-bi ⁇ pyridine] ruthenium (II) ; bis (2,2'-bipyridine) [4-(4'- methyl-2,2'-bipyridine-4'-yl)-butyric acid] ruthenium (II); tris (2,2'bipyridine) ruthenium (II); (2,2'- bipyridine) [bis-bis(l,2-diphenylphosphino)ethylene] 2- [3-(4-methyl-2,2'-bipyridine-4'-yl) ropyl]-1,3-dioxo
  • ECL moieties The function of the ECL moieties is to emit electromagnetic radiation as a result of introduction into the reaction system of electrochemical energy. In order to do this, they must be capable of being stimulated to an excited energy state and also capable of emitting electromagnetic radiation, such as a photon of light, upon descending from that excited state. While not wishing to be bound by theoretical analysis of the mechanism of the ECL moiety's participation in the elec ⁇ trochemiluminescent reaction, we believe that it is oxidized by the introduction of electrochemical energy into the reaction system and then, through interaction with a reductant present in the system, is converted to the excited state. This state is relatively unstable, and the metal chelate quickly descends to a more stable state. In so doing, the chelate gives off electromagnetic radiation, such as a photon of light, which is detectable.
  • the amount of metal chelate or other metal- containing ECL moiety incorporated in accordance with the invention will vary from system to system. Generally, the amount of such moiety utilized is that amount which is effective to result in the emission of a detectable, and if desired, quantitatable , emission of electromagnetic energy, from the aforementioned composition or system.
  • the detection and/or quantitation of an analyte of interest is typically made from a comparison of the luminescence from a sample containing an analyte of interest and an ECL moiety to the luminescence emitted by a calibration standard developed with known amounts of the analyte of interest and ECL moiety. This assumes a homogeneous format. In the heterogeneous mode, a separation as discussed previously is carried out prior to ECL analysis.
  • the particles advantageously comprise micro ⁇ particulate matter having a diameter of 0.001 to 200 ⁇ m, such as 0.05 ⁇ m to 200 ⁇ m, preferably 0.1 ⁇ m to 100 ⁇ m, most preferably 0.5 ⁇ m to 10 ⁇ m, and a surface component capable of binding to the analyte and/or one or more of the other substances defined above.
  • the microparticulate matter may be crosslinked starch, dextrans, cellulose, proteins, organic polymers, styrene copolymer such as styrene/butadiene copolymer, acrylonitrile/butadiene/styrene copolymer, vinylacetyl acrylate copolymer, or vinyl chloride/aerylate copolymer, inert inorganic particles, chromium dioxide, oxides of iron, silica, silica mixtures, and proteinaceous matter, or mixtures thereof.
  • the particles are suspended in the ECL system. However, the particles must be or must include magnetically responsive particles.
  • the electrolyte is a phase through which charge is carried by ions.
  • the electrolyte is in the liquid phase, and is a solution of one or more salts or other species in water, an organic liquid or mixture of organic liquids, or a mixture of water and one or more organic liquids.
  • other forms of electrolyte are also useful in certain embodiments of the invention.
  • the electrolyte may be a dispersion of one or more substances in a fluid —e.g., a liquid, a vapor, or a supercritical fluid —or may be a solution of one or more substances in a solid, a vapor or supercritical fluid.
  • a fluid e.g., a liquid, a vapor, or a supercritical fluid
  • the electrolyte is suitably a solution of a salt in water.
  • the salt can be a sodium salt or a potassium salt preferably, but incorporation of other cations is also suitable in certain embodiments, as long as the cation does not interfere with the electrochemiluminescent interaction sequence.
  • the salt's anion may be a phosphate, for example, but the use of other anions is also permissible in certain embodiments of the invention —once again, as long as the selected anion does not interfere with the electrochemiluminescent interaction sequence.
  • the composition may also be nonaqueous. While supercritical fluids can in certain instances be employed advantageously, it is more typical to utilize an electro ⁇ lyte comprising an organic liquid in a nonaqueous composition. Like an aqueous electrolyte, the nonaqueous electrolyte is also a phase through which charge is carried by ions. Normally, this means that a salt is dissolved in the organic liquid medium. Examples of suitable organic liquids are acetonitrile, dimethylsulfoxide (DMSO) , dimethylformamide (DMF) , methanol, ethanol, and mixtures of two or more of the foregoing. Illustratively, tetraalkylammonium salts, such as tetrabutyla monium tetrafluoroborate, which are soluble in organic liquids can be used with them to form nonaqueous electrolytes.
  • DMSO dimethylsulfoxide
  • DMF dimethylformamide
  • methanol ethanol
  • ethanol ethanol
  • the electrolyte is, in certain embodiments of the invention, a buffered system.
  • Phosphate buffers are often advantageous. Examples are an aqueous solution of sodium phosphate/sodium chloride, and an aqueous solution of sodium phosphate/sodium fluoride.
  • a reductant typically an amine or a ine moiety (of a larger molecule) which can be oxidized and spontaneously decomposed to convert it into a highly reducing species. It is believed that the amine or amine moiety is also oxidized by electrochemical energy introduced into the reaction system. The amine or amine moiety loses one electron, and then deprotonates, or rearranges itself, into a strong reducing agent. This agent interacts with the oxidized metal-containing ECL moiety and causes it to assume the excited state discussed above.
  • a reductant typically an amine or a ine moiety (of a larger molecule) which can be oxidized and spontaneously decomposed to convert it into a highly reducing species. It is believed that the amine or amine moiety is also oxidized by electrochemical energy introduced into the reaction system. The amine or amine moiety loses one electron, and then deprotonates, or rearranges itself, into a strong reducing agent. This agent interacts with the oxidized
  • the amine or amine moiety preferably has a carbon-centered radical with an electron which can be donated from such carbon, and an alpha carbon which can then act as a proton donor during deprotonation in order to form the reductant.
  • the amine-derived reductant provides the necessary stimulus for converting the metal-containing ECL moiety to its excited state, from which detectable electromagnetic radiation is emitted.
  • amines and corresponding amine moieties can be utilized in practicing the present inven ⁇ tion.
  • the amine or amine moiety is chosen to suit the pH of the system which is to be electrochemiluminescently analyzed.
  • Another relevant factor is that the amine or amine moiety should be compatible with the environment in which it must function during analysis, i.e., compatible with an aqueous or nonaqueous environment, as the case may be.
  • the amine or amine moiety selected should form an amine-derived reductant under prevailing conditions which is strong enough to reduce the oxidized metal-containing ECL moiety in the system.
  • Amines (and corresponding moieties derived therefrom) which are advantageously utilized in the present invention are aliphatic amines, such as primary, secondary and tertiary alkyl amines, the alkyl groups of each having from one to three carbon atoms, as well as substituted aliphatic amines.
  • Tripropyl amine is an especially preferred amine as it leads to, comparatively speaking, a particularly high-intensity emission of electromagnetic radiation, which enhances the sensitivity and accuracy of detection and quantitation with embodiments in which it is used.
  • diamines such as hydrazine
  • polymines such as poly(ethyleneimine) .
  • Examples of other amines suitable for practicing the invention are triethanol amine, triethyl amine, l,4-diazabicyclo-(2.2.2)-octane, 1- piperidine ethanol, l,4-piperazine-bis-(ethane-sulfonic acid), tri-isopropyl amine and poly(ethyleneimine) .
  • the metal-containing ECL moiety utilized in the present invention is the reaction- limiting constituent. Accordingly, it is also typical that the amine or amine moiety is provided in a stoichiometric excess with respect thereto. Illustratively, the amine or amine moiety is employed in a concentration of 50-150 mM. For utilization at a pH of approximately 7, a concentration of 100 mM is often advantageous. In certain embodiments, the upper limit on amine or amine moiety concentration is determined by the maximum solubility of the amine or moiety in the environment in which it is being used, for example in water. In general, the amount of amine or amine moiety employed is that which is sufficient to effect the
  • the assays of the invention are desirably carried out in the presence of an enhancer, typically a compound of the formula
  • R is hydrogen or C n H n+1
  • R' is C n H 2n
  • x is 0 to 70
  • n is from 1 to 20.
  • n can be from 1 to 4.
  • Specific examples are a substance available in commerce under the name Triton X-100, of the formula
  • the enhancer is generally utilized in an amount sufficient so that in its presence the desired increase in emission of electromagnetic radiation occurs. Typically, the amount is .01% to 5.0%, more specifically 0.1% to 1.0%, v/v.
  • the ECL moiety used in the present invention is induced to emit electromagnetic radiation by stimulating it into an excited state. This is accomplished by exposing the system in which the ECL moiety is incorporated to electrochemical energy.
  • the potential at which oxidation of the ECL moiety and the species forming a strong reductant occurs depends upon the exact chemical structures thereof, as well as factors such as the pH of the system and the nature of the electrode used to introduce electrochemical energy. It is well known to those of ordinary skill in the art how to determine the optimal potential and emission wavelength of an electro ⁇ chemiluminescent system. Certain preferred methods of stimulating the ECL system are disclosed in PCT published application US 89/01814, the contents of which are incorporated herein by reference.
  • Fig. 8 discloses an advantageous ECL apparatus.
  • the method may be employed in other types of ECL apparatus which include a working electrode or other triggering surface to provide electrochemical energy to trigger the ECL moiety into electrochemiluminescence, and the plurality of north-south magnets. While the methods of the invention can be carried out in a static or flow-through mode, apparatus 10 includes a flow-through cell, which provides distinct advantages for many types of samples including binding assay samples. Further details of apparatus for carrying out the ECL assays of the invention are disclosed in published PCT applications US 89/04854 and U.S. 90/01370.
  • Apparatus 10 includes an electrochemical cell 12, a light detection/measurement device 14, which may advantageously be a photomultiplier tube (PMT) , photodiode, charge coupled device, photographic film or emulsion or the like, and a pump 16, which is advantageously a peristaltic pump, to provide for fluid transport to, through and from cell 12. Alternatively, a positive displacement pump may be used.
  • a shutter mechanism 18 is provided between cell 12 and PMT 14 and is controllably operated to open only so far as to expose PMT 14 to cell 12 during ECL measurement periods. The shutter mechanism may be closed, for example, during maintenance.
  • a lightproof housing intended to mount the various components therein and to shield PMT 14 from any external light during the ECL measurements.
  • Cell 12 itself includes a first mounting block 20 through which passes an inlet tube 22 and an outlet tube 24, which may be advantageously constructed of stainless steel.
  • Mounting block 20 has a first, outer surface 26 and a second, inner surface 28 defining one side of a sample-holding volume 30 of cell 12 in which cell 12 holds the cleaning and/or conditioning and/or measurement solutions during corresponding operations of apparatus 10.
  • Inlet and outlet tubes 22, 24 pass through mounting block 20 from outer surface 26 to inner surface 28 and open into sample-holding volume 30.
  • a second mounting block 32 advantageously constructed of stainless steel also has a first, outer surface 34 and a second, inner surface 36. Second mounting block 32 is separated from first mounting block 20 by an annular spacer 38, advantageously constructed of Teflon or other non-contaminable material.
  • outer surface 34 of mounting block 32 defines part of the second side of the sample-holding volume 30.
  • Spacer 38 has an outer portion 40 and a central aperture 42 whose inner edge 44 defines the side wall of sample-holding volume 30.
  • Outer portion 40 seals the inner surface 28 of first mounting block 20 to outer surface 34 of second mounting block 32 to prevent any solution from passing out from sample-holding volume 30 between the two surfaces 28, 34.
  • Mounting block 32 further has a central aperture 46 in which a window 48 is seal-fitted to define the rest of the second side of sample-holding volume 30 as a continuation of outer surface 34.
  • Window 48 is formed of a material which is substantially transparent at the wavelength of electrochemiluminescent light emitted by the ECL moiety. Window 48 is therefore advantageously formed of glass, plastic, quartz or the like.
  • Inlet tube 22 intersects sample-holding volume 30 at a first end 50 thereof adjacent to spacer 38 and outlet tube 24 intersects sample-holding volume 30 at a second end 52 thereof, adjacent spacer 38.
  • the combination of inlet tube 22, sample-holding volume 30 and outlet tube 24 thereby provides a continuous flow path for the narrow, substantially laminar flow of a solution to, through and from cell 12.
  • Arrows A and B represent the flow into and out of inlet tube 22 and outlet tube 24, respectively.
  • a working electrode system 54 which, in the illustrated embodiment, includes first and second working electrodes 56 and 58.
  • a single working electrode may advantageously be provided, or only electrode 56 may be a working electrode.
  • Working elec ⁇ trodes 56, 58 are where the electrochemical and ECL re ⁇ actions of interest can take place.
  • Working electrodes 56, 58 are solid voltammetric electrodes and may therefore be advantageously constructed of platinum, gold, carbons or other materials which are effective for this purpose.
  • Wire connectors 60, 62 connected to working electrodes 56, 58, respectively, pass out through first mounting block 20.
  • a plurality of magnets 27/37 Positioned vertically below the horizontally oriented electrode 56 or electrodes 56, 58 are a plurality of magnets 27/37 in north-south orientation as shown in Figs, l and 2 and which are discussed in more detail below; see also Figs. 3, 5 and 7 and discussion thereof below.
  • Connectors 60, 62 are both connected to a first, "working electrode” terminal 64 of a voltage
  • Voltage control 66 advantageously operates in the manner of a potentiostat to supply voltage signals to working electrodes 56, 58 and optionally to measure current flowing therefrom during an ECL measurement.
  • connectors 60, 62 may be connected to separate terminals of voltage control 66 for individual operation.
  • 66 is further effected through a counter electrode 68 and, optionally but advantageously, a reference electrode
  • mounting block 32 is made of stainless steel and counter electrode 68 consists in exposed surfaces 72, 74 of mounting block 32.
  • Counter electrode 72, 74 and working electrodes 56, 58 provide the interface to impress the potential on the solution within sample-holding volume 30 which energizes the chemical reactions and triggers electrochemiluminescence in the sample and/or provides energy for cleaning and conditioning the surfaces of cell 12.
  • Counter electrode 72, 74 is connected by a wire connector 76 to a second,
  • Reference electrode 70 provides a reference voltage to which the voltage applied by the working elec ⁇ trodes 56, 58 is referred, for example, +1.2 volts versus the reference.
  • Reference electrode 70 is advantageously located in outlet tube 24 at a position 80 spaced from cell 12 and is connected through a wire connector 82 to a third "reference electrode" terminal 84 of voltage control 66. In the three electrode mode, current may not flow through reference electrode 70.
  • Reference electrode 70 may be used in a three electrode mode of operation to provide a poised, known and stable voltage and is therefore advantageously constructed of silver/silver chloride (Ag/AgCl) or is a saturated calomel electrode (SCE) .
  • Voltage control 66 may be operable in a two electrode mode of operation using only working electrode 56 and electrode 58 as a counter/reference electrode. In this two electrode mode of operation, counter/reference electrode 58 is electrically connected to voltage control terminals 78 and 84 on voltage control 66. In this case, voltage control 66 operates essentially as a battery. Voltage control 66 supplies voltage signals to working and counter electrodes 56 and 58 and optionally measures the current flowing through the respective electrodes.
  • Reference electrode 70 may alternatively be a so-called "quasi-reference" electrode constructed of platinum, gold, stainless steel or other material, which provides a less stable voltage, yet one that is measurable with respect to the solution in contact.
  • the reference electrode 70 or 58 serves the purpose of providing a reference against which the voltage applied to working electrodes 56 is measured.
  • the poised voltage reference is currently considered to be more advantageous.
  • Voltage control 66 in its potentiostat operation controls the various electrodes by providing a known voltage at working electrodes 56, 58 with respect to reference electrode 70 while measuring the current flow between working electrodes 56, 58 and counter electrode 72, 74. Potentiostats for this purpose are well known, and the internal structure of voltage control 66 may therefore correspond to any of the conventional, commercially available potentiostats which produce the above-recited functions and so do not form a part of the present invention per se.
  • apparatus 10 may alternatively be constructed without an internal voltage control 66, and may be adapted to be connected to an external potentiostat which is separately controlled for providing the required voltage signals to electrodes 56, 58, 72, 74 and 70.
  • These voltage signals applied in a specific manner as described below, provide repeatable initial conditions for the surfaces of working electrodes 56, 58 and advantageously for the surfaces of cell 12 as a whole, a feature which contributes significantly to improved precision in ECL measurements.
  • Pump 16 is advantageously positioned at outlet tube 24 to "pull" solution from a sample volume in the direction of arrow A into inlet tube 22.
  • the solution will flow through inlet tube 22, sample-holding volume 30 and outlet tube 24 past reference electrode 70 and out in the direction of arrow B.
  • pump 16 may be positioned at inlet tube 22 to "push” the solution through apparatus 10.
  • this same flow path through inlet tube 22, sample-holding volume 30 and outlet tube 24 is used for all solutions and fluids which pass through cell 12, whereby each fluid performs a hydrodynamic cleaning action in forcing the previous fluid out of cell 12.
  • Pump 16 may be controlled to suspend its operation to hold a particular solution in cell 12 for any period of time.
  • apparatus 10 permits working electrodes to be impressed with a variable voltage or to be continuously held at a preoperative potential while being continuously exposed to one or more solutions without exposing working electrodes 56, 58 (or counter and reference electrodes
  • reagent compositions are used.
  • the reagent compositions are the components of the assay systems of the invention, i.e., (a) electrolyte, (b) label compound containing an ECL moiety, (c) particles, including magnetically responsive particles,
  • SUBSTITUTESHEET (d) analyte of interest or an analog of the analyte of interest, (e) a binding partner of the analyte of interest or of its analog, (f) a reactive component capable of reacting with (d) or (e) , (g) a reductant, or (h) an electrochemiluminescence-reaction enhancer.
  • the reagents may be combined with one another for convenience of use, i.e., two component, three component, and higher multiple component mixtures may be prepared, provided that the components are not reactive with one another during storage so as to impair their function in the intended assay. Desirably, the reagents are two- component or multicomponent mixtures which contain particles as well as one or more other components.
  • the particles are magnetically responsive or include magnetically responsive particles; and have a density of from 1.0 to 5.0 g/mL and preferably have a density of from 1.1 to 2 g/mL.
  • Choice of the optimum density is within the skill of the art, the rate of settling in gravity-driven assays being a trade-off between the speed of the assay and the desire to create a uniform layer of complex on the electrode surface.
  • Particles having a wide range of mean diameters can also be employed. Particles having a mean diameter of from 0.001 to 200 ⁇ m such as 0.05 to 200 ⁇ m can be used; and preferably the particles have a mean diameter of from 0.01 to 10 ⁇ m.
  • concentration of particles in the assay composition can also be employed.
  • concentration can range from 1 to 10,000 ⁇ g/mL to preferably from 5 to 1000 ⁇ g/mL.
  • density of the particles, their size and their concentration is selected such that the particles settle at a rate of at least 0.5 mm/min and preferably at a faster rate.
  • the art has described a number of magnetic particles which can be used in the assays of the invention. For example, U.S. Patent No. 4,628,037, 4,695,392, 4,695,393, 4,698,302, 4,554,088, U.K.
  • the particles may be paramagnetic or ferromagnetic and may be coated with various materials to which binding compounds are coupled so that the magnetic particle can be used in immunoassays.
  • the magnetic particles used in the invention have a susceptibility of at least 0.001 cgs units and desirably the susceptibility is at least 0.01 cgs units.
  • the magnetic particles may have a broad range of densities, i.e. from substantially less than that of water, 0.01, to 5 g/mL and preferably from 0.5 to 2 g/mL.
  • the particle sizes can range from 0.001 to 200, such as 0.001 to 100 or 0.05 to 200 ⁇ m and preferably from 0.01 to 10 ⁇ m.
  • the concentration of the particles may range broadly from 1 to 10,000 ⁇ g per mL and preferably is from 5 to 1000 ⁇ g per mL.
  • the magnetic particles which are used have a low magnetic resonance, as described for example EP 0,180,384, so that after the magnetic field is removed from the electrode surface, the particles demagnetize and can be swept out of the assay cell.
  • the density, concentration and particle size of the magnetic particles is chosen such that the settling time is at least 0.5 mm/min and desirably it is above that rate. In operation of the magnetic cell it is often desirable to remove the magnet means from the electrode surface prior to inducing electrochemiluminescence in order not to interfere with the operation of the photomultiplier tube. Assays
  • a flow-through apparatus as generally shown in
  • Figs. 1, 2, 3, 5, 7, 8 and 9 employing three electrodes, as described in Figs. 8 and 9, and particularly having the plurality of north-south magnets described in Figs. 1 and 2, is used.
  • Inlet Tubing .042" id polypropylene Aspiration Rates:variable from 0.01 to 5 mL/min Potentiostat: microprocessor controlled Luminometer using Hamamatsu R374 PMT (low gain red sensitive tube) ; PMT Voltage variable 0-1400 V (2) Materials
  • Dynal M-450 Dynabeads 4.5 ⁇ m diameter superparamagnetic particles, 30 mg/mL, obtained from Dynal, 45 North Station Plaza, Great Neck, NY 11021
  • Dynal M-280 Dynabeads 2.8 ⁇ M diameter superparamagnetic particles, 10 mg/mL, obtained for Dynal, 45 North
  • the ECL measurement cycle consists of three steps: (l) preconditioning, (2) measuring, and (3) cleaning.
  • the preconditioning step involves the application of a voltage triangle wave of 0.0 V to
  • the measurement step involves the application of a triangle waveform from +0.6 V to +2.8 V to +2.0 V at 1.0 V/s.
  • the cleaning step involves the application of a voltage square wave from +0.0 V to
  • EXAMPLE 1 ECL Apparatus and Method for Deposition of Microparticles. Magnetic Collection using a Sedimentation Cell.
  • a cell such as a sedimentation cell for conduct of an assay using magnetic force generated by the plurality of north-south magnets of Figs. 1 and 2 to cause the microparticulate to settle is shown in Fig. 3.
  • Reference numeral 48 refers to a transparent window, reference numeral 122 to a gasket, reference numeral 22 to the inlet in the cell block, reference numeral 56, 58 to the working electrode, reference numeral 24 to the sample outlet, reference numeral 20 to the cell block itself and reference 27 to the plurality of electromagnets, as shown in Figs. 1 and 2.
  • the plane of the cell block is oriented horizontally; the plurality of magnets 27 is vertically below the magnets.
  • Labeled microparticles (Dynal) in ECL buffer are drawn to the cell by means of a peristaltic pump. The pump is turned off after the microparticles reach the cell.
  • the microparticles in the cell chamber are drawn to the working electrode by means of a magnetic field generated using a plurality of north-south electromagnets as shown in Figs. 1 and 2 and shown generally in Fig. 3 as number 27, which for instance operate at 12 volts and 1.5 amps.
  • the electromagnets By application of the electromagnets, the rate of deposition of microparticles is greatly increased over that observed when the microparticles settle solely due to the force of gravity. This is shown in Fig. 4.
  • FIG. 5 An assay is carried out in a cell such as a collection cell as described in Fig. 5.
  • reference numeral 48 refers to transparent window, reference numeral 132 to a gasket, reference numeral 22 to an inlet in the cell block, reference numeral 56, 58 to a working electrode, reference numeral 20 to the cell block itself, reference numeral 24 to the sample outlet and reference numeral 37 to a plurality of permanent magnets as shown in Figs. 1 and 2.
  • the plane of the cell block is oriented horizontally; the plurality of magnets 37 is vertically below the magnets.
  • Labeled microparticles (Dynal) in ECL buffer are drawn to the electrochemical cell by
  • SHEET means of a peristaltic pump.
  • permanent magnets 37 Prior to the sample introduction, permanent magnets 37 are positioned immediately below the working electrode/solution interface at a distance of 0.035 inches. As the sample is being drawn to the cell, the microparticles deposit onto an area over the working electrode, as defined by the area of the magnets. The pump is turned off and the magnetic field withdrawn after the entire sample is deposited. The longer the collection time, the more particles are deposited. Increasing the concentration of particles on the working electrode results in an increased ECL intensity as shown in Fig. 6.
  • Microparticles 96 which are attracted to a plurality of magnets 27/37 as shown in Figs. 1 and 2, whether they be permanent magnets or electromagnets, align with the orientation of the magnetic field 98, such as in Fig. 7 which depicts magnetic field 98 and the resultant particle arrangement 96 which is parallel to the surface of the working electrode 56/58, in the vicinity of that surface.
  • Figs. 1 and 2 schematically show a cell and magnets 27/37 of Figs. 3, 5, 7, 8 and 9 which is equipped with a magnet system which advantageously imposes field lines which are largely parallel to the plane of the electrode surface 56, 58.
  • the magnet system consists of a plurality of individual permanent or electromagnets which are stacked and oriented such that the north and south poles of the magnets 27/37 alternate in the stack.
  • the individual magnets of magnets 27/37 are separated by air or any non- magnetically responsive material.
  • the arrangement as shown in Figs. 1 and 2 advantageously applies magnetic lines of force to the region above the working electrode which are nearly horizontal to the plane of the electrode. This induces an orientation of the magnetically responsive particles in which the particles lie upon the surface of the electrode and are readily accessible to the electrochemical energy supplied by the electrode; see Fig. 7.
  • the magnet system 27/37 shown in Figs. 1 and 2 also is advantageous in that the magnetic field lines do not extend a long distance from the magnet structure; see Fig. 7.
  • the magnetic field from such a magnet system is not likely, therefore, to induce permanent magnetic behavior on ferromagnetic materials near the electrode apparatus and will not severely affect the operation of a photomultiplier tube near the flow cell apparatus.
  • Uniform and nonuniform, polymeric and non- polymeric, magnetically responsive particles (Dynal, Oslo, Norway; Polysciences, Warrington, PA 18976; Cortex Biochem, San Leandro, CA 94577; Aldrich, Milwaukee, WI 53201) were coated with labeled proteins as described in Example 4.
  • the coated particles were washed with ECL buffer three times before making 2 mL of a 300 ⁇ g/mL suspension. Using a peristaltic pump, 500 ⁇ l of the particle suspension is drawn into the flow cell (Example 2) .
  • Electrochemiluminescence using the magnetic particles is measured using a Hamamatsu R374 photomultiplier tube centered above the flow cell where particles concentrate on the working electrode surface.
  • Table I shows representive ECL photoemission levels obtainable from the labeled-protein coated magnetically responsive particles.
  • Ouabain-BSA Conjugate Reagent II was stored at 4°C.
  • UB S TITUTE SHEET dissolved in 75 ⁇ L of anhydrous dimethyl sulfoxide (Aldrich). To achieve a 50:1 molar ratio of Ru(bpy) 3 2+ label to protein based on molecular weights of 1057 and 150,000 respectively, 0.176mg Ru(bpy) 3 2+ -NHS (26.4 ⁇ L) was added to the protein solution while shaking. The reaction tube was incubated in the dark at room temperature, 30 minutes, while shaking. The reaction was terminated by the addition of 25 ⁇ L of 1M glycine and incubated for 10 minutes.
  • the reaction mixture was purified by passage through a Sephadex G - 25 column (1 X 20 ⁇ m in 0.15M potassium phosphate, 0.15M NaCl with 0.05% sodium azide pH 7.2).
  • the Ru(bpy) 3 2+ -labeled mouse anti- TSH fractions were collected and pooled.
  • the labeled protein (Reagent V) was determined to have 14 labels per protein.
  • Stimulating Hormone (TSH) lOO ⁇ L serum calibrators (London Diagnostics TSH LumiTAG Kit), 25 ⁇ L Ru(bpy) 3 2+ -labeled mouse anti-TSH (Reagent V) in ECL buffer and 25 ⁇ L Sheep anti-TSH-DYNAL particles (Reagent I) in ECL buffer were combined and incubated in polypropylene tubes for 15 minutes, at room temperature, with mixing. Prior to reading results, ImL of ECL buffer was added. The electrochemiluminescence (ECL) for each sample is read as described in Example 2. The ECL counts are directly proportional to the concentration of analyte present in the sample (increasing counts as the concentration of analyte increases) . Table III demonstrates a representative assay curve.
  • EXAMPLE 16 Preparation of Nucleic Acid Magnetic Particles And ECL Use Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . These activated particles were then reacted with oligonucleotides JK8 and JK8C.
  • ECL after hybridization to particles is demonstrated by the hybridization of particles coupled to JK8 and JK8C with Ru(bpy) 3 2+ -label oligonucleotide JK7; JK7 is complementary to the JK8 sequence and not complementary to the JK8C sequence.
  • Individual lots of particles (300 ⁇ g) in ECL buffer are mixed with 50 ⁇ l of ECL buffer containing 12.5, 6.3, 3.01 and 1.5 fmoles of label JK7. These mixtures are hybridized for 4 hours at 52°C followed by washing with ImL ECL buffer and then resuspension on 830 ⁇ l of ECL buffer. The samples are analyzed as described in Example 2.
  • the JK8 particles display over 1000 times more ECL counts than the HK8C particles; at 6.3 fmoles the JK8 particles display nearly 1000 times more ECL counts than the JK8C particles; and, at 3.02 and 1.5 fmoles, the JK8 particles display about 5 and about 3 times more ECL counts than the JK8C particles respectively. This demonstrates the ability to detect by specific hybridization the presence of specific sequences directly immobilized on the surface of particles by ECL.
  • Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . The activated particles were then reacted with streptavidin (Sigma Ltd) . Activated particles (50mg) were washed with 0.1M NaHC0 3 followed by the addition of streptavidin (1.5mg) and reacted overnight. The particles were blocked by the addition of ethanolamine (4mL, 0.1M).
  • the coupled particles were mixed with 0.5mg/mL single stranded salmon sperm DNA in ECL buffer, washed 4-5 times into ECL buffer and resuspended at lOmg/mL in ECL buffer containing lOO ⁇ g/mL single stranded salmon sperm DNA.
  • the streptavidin particles from Dynal M-280 also proved valuable but gives lower signals with the current assay sequence.
  • particles were blocked with BSA after antigen or antibody coupling using the buffers used for passive coating.
  • the particles were finally resuspended in 29.7 mL of ECL diluent and 300 ⁇ l tRNA (lOmg/mL) to a final concentration of 10 mg/mL particles + 100 ⁇ g/mL tRNA.
  • the assay format described here makes use of two oligonucleotides, both of which hybridize to the same DNA strand next to each other, one probe allows capture; the other labels the complex (sandwich hybridization) .
  • This assay was demonstrated using E.coli DNA and probes specific for the trp E/D gene region.
  • the E.coli DNA was prepared following standard protocols (1) .
  • the salmon sperm control DNA was purchased from Sigma Ltd.
  • To the samples of DNA were added 14 ⁇ l of hybridization buffer (10X PBS, lOmMEDTA and 0.7%SDS), 2ng of biotin labeled TRP.C04 and 5ng of Ru(bpy) 3 2+ -label TRP.C03. These samples were made up to lOO ⁇ l with water.
  • the samples were heated to 97°C and incubated at 97°C for lOmin, cooled to 50°C and hybridized for 2hrs.
  • To these samples we added 20 ⁇ l of streptavidin coated magnetic particles II and mixed for 2hrs at room temperature. The particles were then washed 4 times in ECL buffer resuspended in 500 ⁇ l of ECL buffer and are analyzed as described in Example 2.
  • the positive DNA is E.coli and the negative DNA is salmon sperm. The results obtainable are shown in Table VII.
  • streptavidin coated magnetic particles I can be similarly used in the fashion that the streptavidin coated magnetic particles II are used in this example.

Abstract

L'invention se rapporte à des procédés et à un dispositif servant à réaliser une analyse de liaison d'un analyte à étudier présent dans un échantillon, en se basant sur la mesure de la luminescence électrochimique au niveau d'une électrode. Le procédé utilise des particules à sensibilité magnétique. Le procédé et le dispositif mettent en application une pluralité d'électro-aimants ou aimants permanents, orientés dans un sens nord-sud, afin de créer un champ magnétique pour recueillir lesdites particules.
PCT/US1992/000982 1991-02-06 1992-02-05 Procede et dispositif d'analyse utilisant la luminescence magnetique basee sur des microparticules magnetiques et comprenant une pluralite d'aimants WO1992014138A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4507261A JP3013937B2 (ja) 1991-02-06 1992-02-05 複数の磁石を含む磁性微粒子に基づいたルミネッセンス・アッセイのための方法ならびに装置

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65242791A 1991-02-06 1991-02-06
US652,427 1991-02-06
US82726992A 1992-02-03 1992-02-03
US827,269 1992-02-03

Publications (1)

Publication Number Publication Date
WO1992014138A1 true WO1992014138A1 (fr) 1992-08-20

Family

ID=27096296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/000982 WO1992014138A1 (fr) 1991-02-06 1992-02-05 Procede et dispositif d'analyse utilisant la luminescence magnetique basee sur des microparticules magnetiques et comprenant une pluralite d'aimants

Country Status (7)

Country Link
JP (2) JP3013937B2 (fr)
CN (1) CN1107863C (fr)
AU (1) AU1530492A (fr)
IE (1) IE69371B1 (fr)
IL (1) IL100866A (fr)
NZ (1) NZ241538A (fr)
WO (1) WO1992014138A1 (fr)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466416A (en) * 1993-05-14 1995-11-14 Ghaed; Ali Apparatus and methods for carrying out electrochemiluminescence test measurements
US5538687A (en) * 1994-12-16 1996-07-23 Behringer Mannheim Gmbh Apparatus for generating optically detectable signals by applying electrical potentials to sample liquids
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
EP0859230A1 (fr) * 1997-02-10 1998-08-19 Cranfield University Détection d'analytes par électrochemie
EP0859229A1 (fr) * 1997-02-10 1998-08-19 Gist-Brocades B.V. Détection d'analytes par électrochemie
WO1998041867A1 (fr) * 1997-03-18 1998-09-24 Igen International, Inc. Detection de parasites presents dans l'eau par electrochimioluminescence
WO1999039206A1 (fr) * 1998-01-30 1999-08-05 Roche Diagnostics Gmbh Procede d'analyse d'un echantillon selon un essai de reaction de liaison faisant appel a l'electrochimioluminescence
WO2000003233A1 (fr) * 1998-07-10 2000-01-20 Imperial College Of Science, Technology And Medicine Cellule electrochimiluminescente a electrodes de reaction hydrostatiques flottantes
US6100045A (en) * 1997-02-10 2000-08-08 Dsm N.V. Detection of analytes using electrochemistry
EP1042508A1 (fr) * 1997-12-23 2000-10-11 Meso Scale Technologies LLC Procedes et appareil pour dosages a luminescence amelioree utilisant des microparticules
US6132955A (en) * 1995-05-18 2000-10-17 Igen International, Inc. Method for derivitizing electrodes and assay methods using such derivitized electrodes
US6136268A (en) * 1999-08-17 2000-10-24 Orion Diagnostica Method for luminescence measurements
EP1325333A1 (fr) * 2000-10-10 2003-07-09 Aviva Biosciences Corporation Puces a ensembles d'unites micro-electromagnetiques adressables individuellement en configurations horizontales
WO2003096014A2 (fr) * 2002-05-08 2003-11-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Determination d'un analyte dans un support liquide
AT413153B (de) * 2004-03-11 2005-11-15 Christian Doppler Labor Fuer S Verfahren und vorrichtung zur detektion von markierten mikropartikeln
WO2007101661A1 (fr) 2006-03-09 2007-09-13 F.Hoffmann-La Roche Ag Dosage d'anticorps antimédicament
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
WO2008031532A1 (fr) 2006-09-12 2008-03-20 F. Hoffmann-La Roche Ag Essai d'anticorps anti-médicament
WO2008104344A1 (fr) 2007-02-27 2008-09-04 F. Hoffmann-La Roche Ag Procédé pour l'évaluation de l'activité inhibitrice d'anticorps à l'encontre du récepteur du facteur de croissance i de type insuline
WO2009077127A1 (fr) 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Dosage de distinction
WO2010072384A1 (fr) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Anticorps anti-idiotype dirigé contre un anticorps dirigé contre le peptide amyloïde β
WO2012022774A1 (fr) 2010-08-19 2012-02-23 Roche Diagnostics Gmbh Dosage pour la mesure d'anticorps se liant à un anticorps monoclonal thérapeutique
WO2012143380A1 (fr) 2011-04-20 2012-10-26 F. Hoffmann-La Roche Ag Hyperfréquences pour analyse immunohistochimique
WO2012175508A1 (fr) 2011-06-22 2012-12-27 F. Hoffmann-La Roche Ag Élimination de cellules cibles par des cellules t cytotoxiques circulantes spécifiques du virus à l'aide de complexes comprenant des molécules du cmh de classe i
WO2013092611A2 (fr) 2011-12-19 2013-06-27 F. Hoffmann - La Roche Ag Procédé pour la détection d'un partenaire de liaison libre d'un liant multispéficique
WO2013113663A1 (fr) 2012-02-01 2013-08-08 F. Hoffmann-La Roche Ag Procédé de détection d'un partenaire de liaison d'un liant multispécifique
WO2013132000A1 (fr) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Procédé de dosage immunologique et de chromatographie en phase multiplexée pour la caractérisation de complexes immunitaires circulants
EP2573562A3 (fr) * 2007-02-09 2013-10-30 Advanced Liquid Logic, Inc. Dispositifs actionneurs de gouttelettes et procédés utilisant des billes magnétiques
WO2014009474A1 (fr) 2012-07-13 2014-01-16 F. Hoffmann-La Roche Ag Procédé de détection d'un liant multispécifique
WO2015000865A1 (fr) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Dosage immunologique à interférence supprimé et pour détecter des anticorps anti-médicament dans des échantillons de sérum
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
WO2017072210A1 (fr) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anticorps anti-région fc variante et procédés d'utilisation
WO2017093226A1 (fr) 2015-11-30 2017-06-08 F. Hoffmann-La Roche Ag Immuno-essai pour la détermination d'anticorps modifiés de la région fc
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
WO2019105916A1 (fr) 2017-11-29 2019-06-06 F. Hoffmann-La Roche Ag Dosage d'anticorps anti-médicament à interférence de cible supprimée
US10501521B2 (en) 2012-12-21 2019-12-10 Hoffmann-La Roche Inc. Disulfide-linked multivalent MHC class I comprising multi-function proteins
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10677695B2 (en) 2002-11-07 2020-06-09 Lsi Medience Corporation Magnetic material for collecting magnetic particles and utilization thereof
WO2020141145A1 (fr) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anticorps anti-lapin cd19 et procédés d'utilisation
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
WO2020229378A1 (fr) 2019-05-13 2020-11-19 F. Hoffmann-La Roche Ag Dosage immunologique pharmacocinétique à interférence supprimée
WO2021136772A1 (fr) 2020-01-02 2021-07-08 F. Hoffmann-La Roche Ag Procédé de détermination de la quantité d'un anticorps thérapeutique dans le cerveau
WO2021254926A1 (fr) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Procédé de détermination de l'antigène libre d'un anticorps dans un échantillon
WO2022214565A1 (fr) 2021-04-09 2022-10-13 F. Hoffmann-La Roche Ag Procédé de sélection de clones cellulaires exprimant un polypeptide hétérologue
WO2023021055A1 (fr) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Anticorps à région fc anti-variant multivalente et méthode d'utilisation
WO2023117325A1 (fr) 2021-12-21 2023-06-29 F. Hoffmann-La Roche Ag Procédé pour déterminer l'activité hydrolytique
WO2024044622A1 (fr) 2022-08-24 2024-02-29 Amgen Inc. Dosages d'anticorps anti-médicament

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6744894B1 (en) 1994-04-01 2004-06-01 Mitsubishi Corporation Data management system
US7036019B1 (en) 1994-04-01 2006-04-25 Intarsia Software Llc Method for controlling database copyrights
JPH07271865A (ja) 1994-04-01 1995-10-20 Mitsubishi Corp データベース著作権管理方法
US6424715B1 (en) 1994-10-27 2002-07-23 Mitsubishi Corporation Digital content management system and apparatus
DE69532434T2 (de) 1994-10-27 2004-11-11 Mitsubishi Corp. Gerät für Dateiurheberrechte-Verwaltungssystem
EP0709760B1 (fr) 1994-10-27 2006-05-31 Intarsia Software LLC Système de gestion de données de droits d'auteurs
US8595502B2 (en) 1995-09-29 2013-11-26 Intarsia Software Llc Data management system
US7801817B2 (en) 1995-10-27 2010-09-21 Makoto Saito Digital content management system and apparatus
JP4763866B2 (ja) 1998-10-15 2011-08-31 インターシア ソフトウェア エルエルシー ２重再暗号化によりデジタルデータを保護する方法及び装置
DE60027578T2 (de) * 1999-07-16 2007-01-25 WM. Marsh Rice University, Houston Verfahren zum Nachweis von Bioanalyten unter Verwendung metallischer Nanohüllen
US6518747B2 (en) * 2001-02-16 2003-02-11 Quantum Design, Inc. Method and apparatus for quantitative determination of accumulations of magnetic particles
GB0812679D0 (en) * 2008-07-10 2008-08-20 Sec Dep For Innovation Universities Sample carrier for effecting chemical assays
JP5481326B2 (ja) * 2010-09-08 2014-04-23 株式会社日立製作所 生体物質検出用素子を用いた計測装置及び計測方法
EP2634579B1 (fr) * 2012-03-03 2014-12-17 Astrium GmbH Procédé d'exécution de dosages immunologiques en apesanteur
CN104471380B (zh) * 2012-07-06 2017-11-17 株式会社日立高新技术 分析装置以及分析方法
CN103954664A (zh) * 2014-04-10 2014-07-30 深圳普门科技有限公司 一种电极盘及其制备方法和基于此电极盘的电化学流动池
WO2018226891A1 (fr) * 2017-06-06 2018-12-13 Northwestern University Separation magnetique trans-interfaciale

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030087A1 (fr) * 1979-11-13 1981-06-10 Technicon Instruments Company Limited Procédé et dispositif d'immuno-essais et trousse pour mise en oeuvre de ce procédé
US4431919A (en) * 1980-04-10 1984-02-14 U.S. Philips Corporation Detection apparatus, particularly for use in liquid chromatography
WO1986005815A1 (fr) * 1985-03-25 1986-10-09 Genetics International Inc. Sequences d'acide nucleique liees a des materiaux sensibles a des champs magnetiques, et methodes d'analyse et appareils utilisant lesdites sequences liees
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
WO1987006706A1 (fr) * 1986-04-30 1987-11-05 Igen, Inc. Analyses electrochimiluminescentes
US5061445A (en) * 1988-11-03 1991-10-29 Igen, Inc. Apparatus for conducting measurements of electrochemiluminescent phenomena
US5068088A (en) * 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
US5093268A (en) * 1988-04-28 1992-03-03 Igen, Inc. Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) * 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030087A1 (fr) * 1979-11-13 1981-06-10 Technicon Instruments Company Limited Procédé et dispositif d'immuno-essais et trousse pour mise en oeuvre de ce procédé
US4431919A (en) * 1980-04-10 1984-02-14 U.S. Philips Corporation Detection apparatus, particularly for use in liquid chromatography
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
WO1986005815A1 (fr) * 1985-03-25 1986-10-09 Genetics International Inc. Sequences d'acide nucleique liees a des materiaux sensibles a des champs magnetiques, et methodes d'analyse et appareils utilisant lesdites sequences liees
WO1987006706A1 (fr) * 1986-04-30 1987-11-05 Igen, Inc. Analyses electrochimiluminescentes
US5093268A (en) * 1988-04-28 1992-03-03 Igen, Inc. Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena
US5061445A (en) * 1988-11-03 1991-10-29 Igen, Inc. Apparatus for conducting measurements of electrochemiluminescent phenomena
US5068088A (en) * 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMM., Volume 128, No. 2, issued 30 April 1985, Y. IKARIYAMA et al., "Electrochemical Luminescence-Based Homogeneous Immunoassay", pages 987-992. *
CLIN. CHEM., Volume 26, No. 6, issued 1980, M. POURFARZANEH et al., "Cortisol Directly Determinedin Serum by Fluoroimmunoassay with Magnetizable Solid Phase", pages 730-733. *
CLIN. CHEM., Volume 26, No. 9, issued September 1980, R.S. KAMEL et al., "Magnetizable Solid Phase Fluoroimmunoassay of Phenyltoin in Disposable Test Tubes", pages 1881-1284. *
CLIN. CHEM., Volume 37, No. 9, issued September 1991, J.H. KENTEN et al., "Rapid Electrochemiluminescence Assays of Polymerase Chain Reaction Products", pages 1626-1632. *
J. ALLERGY AND CLIN. IMM., Volume 61, No. 1, issued January 1978, J.L. GUESDON et al., "Magnetic Enzyme Immunoassay for Measuring Human IGE", pages 23-27. *
NUCLEIC ACIDS RESEARCH, Vol. 16, No. 11, issued 1988, M.S. URDEA et al., "A Comparison of Nonradioisotopichybridization Assay Methods Using Chemiluminescent and Enzyme Labeled Synthetic Oligodeoxyribonucleotide Probes", pages 4937-4956. *

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720922A (en) * 1993-05-14 1998-02-24 Igen International, Inc. Instrument incorporating electrochemiluminescent technology
US5466416A (en) * 1993-05-14 1995-11-14 Ghaed; Ali Apparatus and methods for carrying out electrochemiluminescence test measurements
US5543112A (en) * 1993-05-14 1996-08-06 Igen, Inc. Apparatus and methods for carrying out electrochemiluminescence test measurements
US5624637A (en) * 1993-05-14 1997-04-29 Igen, Inc. Apparatus and methods for carrying out electrochemiluminescence test measurements
US5632956A (en) * 1993-05-14 1997-05-27 Igen, Inc. Apparatus and methods for carrying out electrochemiluminescence test measurements
US5700427A (en) * 1993-05-14 1997-12-23 Igen International, Inc. Apparatus for carrying out electrochemiluminescence test measurements
EP0871864A4 (fr) * 1994-11-10 1999-02-10 Igen Inc Appareil et methode de detection des particules magnetiques d'apres la luminescence electrochimique
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
EP0871864A1 (fr) * 1994-11-10 1998-10-21 Igen, Inc. Appareil et methode de detection des particules magnetiques d'apres la luminescence electrochimique
US6133043A (en) * 1994-11-10 2000-10-17 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
US5538687A (en) * 1994-12-16 1996-07-23 Behringer Mannheim Gmbh Apparatus for generating optically detectable signals by applying electrical potentials to sample liquids
US6846629B2 (en) 1995-05-09 2005-01-25 Mesoscale Technologies, Llc. Methods and apparatus for improved luminescence assays using microparticles
US6132955A (en) * 1995-05-18 2000-10-17 Igen International, Inc. Method for derivitizing electrodes and assay methods using such derivitized electrodes
EP0859230A1 (fr) * 1997-02-10 1998-08-19 Cranfield University Détection d'analytes par électrochemie
EP0859229A1 (fr) * 1997-02-10 1998-08-19 Gist-Brocades B.V. Détection d'analytes par électrochemie
US6100045A (en) * 1997-02-10 2000-08-08 Dsm N.V. Detection of analytes using electrochemistry
WO1998041867A1 (fr) * 1997-03-18 1998-09-24 Igen International, Inc. Detection de parasites presents dans l'eau par electrochimioluminescence
US6146838A (en) * 1997-03-18 2000-11-14 Igen International, Inc. Detecting water-borne parasites using electrochemiluminescence
EP1042508A1 (fr) * 1997-12-23 2000-10-11 Meso Scale Technologies LLC Procedes et appareil pour dosages a luminescence amelioree utilisant des microparticules
EP2186910A3 (fr) * 1997-12-23 2011-04-06 Meso Scale Technologies LLC Procédés et compositions pour dosages a luminescence ameliorée utilisant des microparticules
EP1042508A4 (fr) * 1997-12-23 2002-05-29 Meso Scale Technologies Llc Procedes et appareil pour dosages a luminescence amelioree utilisant des microparticules
US9448235B2 (en) 1997-12-23 2016-09-20 Meso Scale Technologies Llc. Methods and apparatus for improved luminescence assays using microparticles
US6599473B1 (en) 1998-01-30 2003-07-29 Roche Diagnostics Gmbh Electrochemilumiscence method for detecting analytes
WO1999039206A1 (fr) * 1998-01-30 1999-08-05 Roche Diagnostics Gmbh Procede d'analyse d'un echantillon selon un essai de reaction de liaison faisant appel a l'electrochimioluminescence
WO2000003233A1 (fr) * 1998-07-10 2000-01-20 Imperial College Of Science, Technology And Medicine Cellule electrochimiluminescente a electrodes de reaction hydrostatiques flottantes
US6696020B1 (en) 1998-07-10 2004-02-24 Imperial College Of Science, Technology And Medicine Electrochemiluminescence cell with floating reaction electrodes
US6136268A (en) * 1999-08-17 2000-10-24 Orion Diagnostica Method for luminescence measurements
EP1325333A1 (fr) * 2000-10-10 2003-07-09 Aviva Biosciences Corporation Puces a ensembles d'unites micro-electromagnetiques adressables individuellement en configurations horizontales
EP1325333A4 (fr) * 2000-10-10 2006-03-22 Aviva Biosciences Corp Puces a ensembles d'unites micro-electromagnetiques adressables individuellement en configurations horizontales
WO2003096014A3 (fr) * 2002-05-08 2004-03-04 Yissum Res Dev Co Determination d'un analyte dans un support liquide
WO2003096014A2 (fr) * 2002-05-08 2003-11-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Determination d'un analyte dans un support liquide
US10677695B2 (en) 2002-11-07 2020-06-09 Lsi Medience Corporation Magnetic material for collecting magnetic particles and utilization thereof
AT413153B (de) * 2004-03-11 2005-11-15 Christian Doppler Labor Fuer S Verfahren und vorrichtung zur detektion von markierten mikropartikeln
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
WO2007101661A1 (fr) 2006-03-09 2007-09-13 F.Hoffmann-La Roche Ag Dosage d'anticorps antimédicament
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
WO2008031532A1 (fr) 2006-09-12 2008-03-20 F. Hoffmann-La Roche Ag Essai d'anticorps anti-médicament
EP2573562A3 (fr) * 2007-02-09 2013-10-30 Advanced Liquid Logic, Inc. Dispositifs actionneurs de gouttelettes et procédés utilisant des billes magnétiques
US10379112B2 (en) 2007-02-09 2019-08-13 Advanced Liquid Logic, Inc. Droplet actuator devices and methods employing magnetic beads
WO2008104344A1 (fr) 2007-02-27 2008-09-04 F. Hoffmann-La Roche Ag Procédé pour l'évaluation de l'activité inhibitrice d'anticorps à l'encontre du récepteur du facteur de croissance i de type insuline
WO2009077127A1 (fr) 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Dosage de distinction
US8227195B2 (en) 2007-12-15 2012-07-24 Hoffman-La Roche Inc. Distinguishing assay
EP2573568A1 (fr) 2007-12-15 2013-03-27 F. Hoffmann-La Roche AG Analyse de distinction
US8530176B2 (en) 2007-12-15 2013-09-10 Hoffmann-La Roche Inc. Distinguishing assay
WO2010072384A1 (fr) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Anticorps anti-idiotype dirigé contre un anticorps dirigé contre le peptide amyloïde β
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
WO2012022774A1 (fr) 2010-08-19 2012-02-23 Roche Diagnostics Gmbh Dosage pour la mesure d'anticorps se liant à un anticorps monoclonal thérapeutique
US9081016B2 (en) 2010-08-19 2015-07-14 Roche Diagnostics Operations, Inc. Assay for measurement of antibodies binding to a therapeutic monoclonal antibody
WO2012143380A1 (fr) 2011-04-20 2012-10-26 F. Hoffmann-La Roche Ag Hyperfréquences pour analyse immunohistochimique
WO2012175508A1 (fr) 2011-06-22 2012-12-27 F. Hoffmann-La Roche Ag Élimination de cellules cibles par des cellules t cytotoxiques circulantes spécifiques du virus à l'aide de complexes comprenant des molécules du cmh de classe i
WO2013092611A2 (fr) 2011-12-19 2013-06-27 F. Hoffmann - La Roche Ag Procédé pour la détection d'un partenaire de liaison libre d'un liant multispéficique
US10761097B2 (en) 2012-02-01 2020-09-01 Hoffmann-La Roche Inc. Method for the detection of a binding partner of a multispecific binder
WO2013113663A1 (fr) 2012-02-01 2013-08-08 F. Hoffmann-La Roche Ag Procédé de détection d'un partenaire de liaison d'un liant multispécifique
US9945869B2 (en) 2012-02-01 2018-04-17 Hoffmann-La Roche Inc. Method for the detection of a binding partner of a multispecific binder
WO2013132000A1 (fr) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Procédé de dosage immunologique et de chromatographie en phase multiplexée pour la caractérisation de complexes immunitaires circulants
WO2014009474A1 (fr) 2012-07-13 2014-01-16 F. Hoffmann-La Roche Ag Procédé de détection d'un liant multispécifique
US10501521B2 (en) 2012-12-21 2019-12-10 Hoffmann-La Roche Inc. Disulfide-linked multivalent MHC class I comprising multi-function proteins
WO2015000865A1 (fr) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Dosage immunologique à interférence supprimé et pour détecter des anticorps anti-médicament dans des échantillons de sérum
WO2017072210A1 (fr) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anticorps anti-région fc variante et procédés d'utilisation
WO2017093226A1 (fr) 2015-11-30 2017-06-08 F. Hoffmann-La Roche Ag Immuno-essai pour la détermination d'anticorps modifiés de la région fc
WO2019105916A1 (fr) 2017-11-29 2019-06-06 F. Hoffmann-La Roche Ag Dosage d'anticorps anti-médicament à interférence de cible supprimée
WO2020141145A1 (fr) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anticorps anti-lapin cd19 et procédés d'utilisation
WO2020229378A1 (fr) 2019-05-13 2020-11-19 F. Hoffmann-La Roche Ag Dosage immunologique pharmacocinétique à interférence supprimée
WO2021136772A1 (fr) 2020-01-02 2021-07-08 F. Hoffmann-La Roche Ag Procédé de détermination de la quantité d'un anticorps thérapeutique dans le cerveau
WO2021254926A1 (fr) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Procédé de détermination de l'antigène libre d'un anticorps dans un échantillon
WO2022214565A1 (fr) 2021-04-09 2022-10-13 F. Hoffmann-La Roche Ag Procédé de sélection de clones cellulaires exprimant un polypeptide hétérologue
WO2023021055A1 (fr) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Anticorps à région fc anti-variant multivalente et méthode d'utilisation
WO2023117325A1 (fr) 2021-12-21 2023-06-29 F. Hoffmann-La Roche Ag Procédé pour déterminer l'activité hydrolytique
WO2024044622A1 (fr) 2022-08-24 2024-02-29 Amgen Inc. Dosages d'anticorps anti-médicament

Also Published As

Publication number Publication date
IE920381A1 (en) 1992-08-12
AU1530492A (en) 1992-09-07
IE69371B1 (en) 1996-09-04
CN1065339A (zh) 1992-10-14
JPH06508203A (ja) 1994-09-14
JPH11125601A (ja) 1999-05-11
JP3013937B2 (ja) 2000-02-28
JP3128541B2 (ja) 2001-01-29
CN1107863C (zh) 2003-05-07
IL100866A (en) 1995-10-31
NZ241538A (en) 1993-02-25

Similar Documents

Publication Publication Date Title
US5705402A (en) Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
EP0570518B1 (fr) Procede et appareil permettant d'effectuer des dosages ameliores bases sur la electrochemi-luminescence
US5935779A (en) Methods for improved particle electrochemiluminescence assay
WO1992014138A1 (fr) Procede et dispositif d'analyse utilisant la luminescence magnetique basee sur des microparticules magnetiques et comprenant une pluralite d'aimants
US6325973B1 (en) Methods and apparatus for improved luminescence assays
US5779976A (en) Apparatus for improved luminescence assays
US5962218A (en) Methods and apparatus for improved luminescence assays
AU637775B2 (en) Electrochemiluminescent assays
US5746974A (en) Apparatus for improved luminescence assays using particle concentration, electrochemical generation of chemiluminescence and chemiluminescence detection
EP0594766B1 (fr) Methodes pour dosages par luminescence ameliores utilisant une concentration particulaire et la detection par chimioluminescence
US5770459A (en) Methods and apparatus for improved luminescence assays using particle concentration, electrochemical generation of chemiluminescence detection
US6881589B1 (en) Electrochemiluminescent localizable complexes for assay compositions
US7462322B2 (en) Methods and apparatus for improved luminescence assays
AU676665C (en) Methods and apparatus for improved luminescence assays usingparticle concentration and chemiluminescence detection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA